CN107988246A - 一种基因敲除载体及其斑马鱼胶质瘤模型 - Google Patents
一种基因敲除载体及其斑马鱼胶质瘤模型 Download PDFInfo
- Publication number
- CN107988246A CN107988246A CN201810011807.3A CN201810011807A CN107988246A CN 107988246 A CN107988246 A CN 107988246A CN 201810011807 A CN201810011807 A CN 201810011807A CN 107988246 A CN107988246 A CN 107988246A
- Authority
- CN
- China
- Prior art keywords
- gene
- zebrafish
- gene knockout
- knockout
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000252212 Danio rerio Species 0.000 title claims abstract description 72
- 238000003209 gene knockout Methods 0.000 title claims abstract description 63
- 206010018338 Glioma Diseases 0.000 title claims abstract description 54
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 33
- 239000013598 vector Substances 0.000 claims abstract description 50
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 108091033409 CRISPR Proteins 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000013612 plasmid Substances 0.000 claims abstract description 16
- 102000004190 Enzymes Human genes 0.000 claims abstract description 12
- 108090000790 Enzymes Proteins 0.000 claims abstract description 12
- 101150080074 TP53 gene Proteins 0.000 claims abstract description 12
- 238000010362 genome editing Methods 0.000 claims abstract description 9
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 claims abstract description 5
- 241000251468 Actinopterygii Species 0.000 claims description 48
- 235000013601 eggs Nutrition 0.000 claims description 25
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims description 20
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 20
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 20
- 108020005004 Guide RNA Proteins 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 14
- 230000017105 transposition Effects 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 10
- 230000006798 recombination Effects 0.000 claims description 10
- 238000005215 recombination Methods 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 238000010171 animal model Methods 0.000 claims description 6
- 238000010276 construction Methods 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 5
- 102000034287 fluorescent proteins Human genes 0.000 claims description 5
- 108700026223 Neurofibromatosis 1 Genes Proteins 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 108010054624 red fluorescent protein Proteins 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 abstract description 14
- 201000011614 malignant glioma Diseases 0.000 abstract description 14
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 238000005516 engineering process Methods 0.000 abstract description 11
- 238000010354 CRISPR gene editing Methods 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 7
- 230000008506 pathogenesis Effects 0.000 abstract description 6
- 230000002068 genetic effect Effects 0.000 abstract description 5
- 101150083321 Nf1 gene Proteins 0.000 abstract description 3
- 230000033115 angiogenesis Effects 0.000 abstract description 3
- 108700019146 Transgenes Proteins 0.000 abstract description 2
- 238000001823 molecular biology technique Methods 0.000 abstract description 2
- 210000000130 stem cell Anatomy 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 239000000243 solution Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 28
- 238000002347 injection Methods 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 239000007788 liquid Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 21
- 239000000499 gel Substances 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 230000019491 signal transduction Effects 0.000 description 14
- 239000002699 waste material Substances 0.000 description 13
- 210000002257 embryonic structure Anatomy 0.000 description 11
- 230000000366 juvenile effect Effects 0.000 description 10
- 238000011084 recovery Methods 0.000 description 10
- 239000011543 agarose gel Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 238000000246 agarose gel electrophoresis Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000012160 loading buffer Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 230000007730 Akt signaling Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 230000022963 DNA damage response, signal transduction by p53 class mediator Effects 0.000 description 4
- 206010064571 Gene mutation Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000223785 Paramecium Species 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000005192 partition Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 238000009372 pisciculture Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- 108700024526 zebrafish sox32 Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 101150057182 GFAP gene Proteins 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 108010045673 endodeoxyribonuclease XBAI Proteins 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供一种基因敲除载体及其斑马鱼胶质瘤模型,该基因敲除载体为将目的序列连入可表达CRISPR‑Cas9基因编辑系统相关酶的质粒获得,该目的基因为p53、Rb1或Nf1基因。本发明利用CRISPR/CAS9技术,靶向敲除rb1、nf1和tp53基因,建立的转基因诱导恶性胶质瘤斑马鱼模型,可以通过实时荧光观察恶性胶质瘤的发生、肿瘤诱导血管生成、胶质瘤干细胞发生过程,并通过分子生物学技术探讨不同遗传背景条件下胶质瘤的发病机制差异。
Description
技术领域
本发明涉及CRISPR/Cas9的基因修饰技术领域,特别是涉及利用该技术在不破坏基因的情况下使用内源性启动子诱导荧光蛋白表达的方法,具体涉及一种基因敲除载体及其斑马鱼胶质瘤模型。
背景技术
CRISPR/Cas9(Clustered Regularly Interspaced Short Palindromic Repeat/CRISPR-associated nuclease 9)基因编辑系统是基于古细菌抵御外源核酸入侵的免疫机制为基础开发出来的一种新型的基因编辑技术。相对于传统的基因编辑系统,该系统具有突变效率高、制作简单及成本低的特点。目前该技术成功应用于人类细胞、斑马鱼、小鼠以及细菌的基因组精确修饰,修饰类型包括基因定点敲除、基因定点敲入、两位点同时突变和小片段的缺失。
近年来,随着基因测序技术和高通量基因芯片技术的发展,大量研究发现恶性胶质瘤的发生伴随着大量的染色体异常和基因突变。2009年,癌症与肿瘤基因图谱计划(TheCancer Genome Atlas;TCGA)发现在超过200个人恶性胶质瘤病理样本中,通过分析DNA甲基化、DNA拷贝数的变化,以及胶质瘤相关编码蛋白及非编码蛋白基因表达水平,研究显示,与胶质瘤发生最为相关的三个信号通路分别是p53信号通路、Rb信号通路和RTK/PI3K/Akt信号通路。这三种信号通路主要与细胞增殖,包括肿瘤细胞免疫逃逸和细胞周期检查点(checkpoint)相关的细胞生存、衰老,以及细胞凋亡相关(见图1A和图1B)。
RTK和PI3K/Akt信号通路组成的跨膜蛋白,通常具有介导多种生长因子表达水平的酪氨酸激酶活性(图1A)。有文献表明,多个RTK的配体如血管内皮生长因子(EGFR)、血管内皮生长因子受体(VEGFR)以及血小板衍生生长因子受体(PDGFR)均与恶性胶质瘤的发生相关。其中,EGFR是一种RTK配体的共同靶基因,大约有40%的原发性恶性胶质瘤中都有发现其突变,同时,EGFR的表达异常往往与p53基因突变相关。在已报道的包含有基因突变的恶性胶质瘤病例中,大约有88%的病例具有PI3K基因突变。在这一信号通路中,其上游Nf1抑癌基因的抑制可以激活PI3K/Akt信号通路,最终导致多种恶性肿瘤的形成。
在恶性胶质瘤发生过程中,另一种关键的信号通路为p53信号通路(图1B)。作为最经典的肿瘤抑制基因,p53在恶性胶质瘤的发生发展中起重要的作用。p53可以调控多个控制DNA修复、细胞周期、凋亡和进展的基因表达水平。p53的突变常常可以发展出各种肿瘤,包括恶性胶质瘤,同时,原发性p53肿瘤细胞突变可以极大地促进肿瘤转化和生长的易感性。然而,无论是p53杂合子(p53-/+)或是p53纯合子(p53-/-)转基因小鼠,均不能发展为星形细胞瘤,提示仅仅p53的突变并不足以介导肿瘤的形成,可能需要额外的表观遗传学(或遗传学)事件介导肿瘤的生成。Rb信号通路主要包括若干肿瘤抑制基因(图1B),可以调控一系列肿瘤相关因子的表达水平。在恶性胶质瘤中,大约有40-70%的病例与Rb信号通路相关基因的突变有关。这一信号通路主要与DNA的修复和复制、细胞分化、细胞凋亡、细胞周期的调控等生物学事件相关。已有研究表明,Rb信号通路介导的遗传学和表观遗传学的调控与多种肿瘤的发生发展具有密切的关系。
综上所述,p53信号通路、Rb信号通路和RTK/PI3K/Akt信号通路是导致恶性胶质瘤发生、发展的最为关键信号通路。有研究表明,90%以上的恶性胶质瘤病例中发现至少有其中有一条通路失活,提示这三个信号通路可能是恶性胶质瘤治疗的关键性靶点。
之前,Chow等进行了构建转基因胶质瘤小鼠的研究,在该报道中,当Nf1、p53和Pten三个基因都被敲除后,100%的小鼠产生了胶质瘤,而且大多是恶性程度很高的肿瘤。尽管胶质瘤转基因小鼠中目前在研究肿瘤发病机制中发挥重要作用,但其胚胎发育的特点并不利于实时观察肿瘤发生的过程。
发明内容
鉴于以上所述现有技术的缺点,本发明的目的在于提供一种基因敲除载体及其斑马鱼胶质瘤模型,用于解决现有技术中基于胶质瘤的动物模型容易导致动物胚胎致死、难以适用于阐述不同遗传背景的胶质瘤患者发病机制等问题。
为实现上述目的及其他相关目的,本发明第一方面提供一种基因敲除载体,所述基因敲除载体为将目的序列连入可表达CRISPR-Cas9基因编辑系统相关酶的质粒获得,所述目的序列选自如下序列中的至少一种:
rb1:TGCATGGAGAATATGGGAGA;
nf1:GGCGCACAAGCCCGTGGAAT;
tp53:TGATTGTGAGGATGGGCCTG。
在本发明的一些实施例中,所述可表达CRISPR-Cas9基因编辑系统相关酶的质粒为Cas9-pXT7质粒。
在本发明的一些实施例中,所述基因敲除载体还含有标记基因mCherry。
在本发明的一些实施例中,所述基因敲除载体还含有GFAP启动子启动的CAS9蛋白序列、融合蛋白P2A序列、标记基因mCherry、U6启动子启动的gRNA。
在本发明的一些实施例中,所述基因敲除载体序列如SEQ ID NO.1所示。
本发明第二方面提供上述基因敲除载体在构建胶质瘤动物模型中的用途。
在本发明的一些实施例中,所述动物模型包括鱼、鼠、兔。
在本发明的一些实施例中,所述动物模型为斑马鱼。
本发明第三方面提供一种建立斑马鱼胶质瘤模型的方法,包括如下步骤:
1)确立p53、Rb1和Nf1基因打靶位点以及打靶序列,合成gRNA;
p53、Rb1和Nf1基因含有如下目标序列:
rb1:TGCATGGAGAATATGGGAGA;
nf1:GGCGCACAAGCCCGTGGAAT;
tp53:TGATTGTGAGGATGGGCCTG;
2)构建基因敲除转座重组载体;
3)将基因敲除转座重组载体和Tol2mRNA共同注射入斑马鱼单细胞期受精卵中,实现目的基因整合进入基因组;
4)筛选并鉴定出能够稳定敲除上述三种基因的纯种斑马鱼;
5)筛选出双基因或多基因敲除的纯系斑马鱼。
在本发明的一些实施例中,步骤2)中,所述重组载体包括GFAP启动子启动的CAS9蛋白序列、融合蛋白P2A序列、标记基因mCherry、U6启动子启动的gRNA。
在本发明的一些实施例中,步骤2)中,所述重组载体序列如SEQ ID NO.1所示。
在本发明的一些实施例中,步骤2)中所构建的重组载体Cas9的启动子为GFAP,序列如SEQ ID NO.2所示。
在本发明的一些实施例中,步骤2)中所构建的重组载体的筛选基因为红色荧光蛋白mCherry,序列如SEQ ID NO.3所示。
在本发明的一些实施例中,步骤2)中所构建的重组载体靶位点的启动子为U6启动子,序列如SEQ ID NO.4所示。
在本发明的一些实施例中,步骤1)中,构建打靶序列gRNA时,合成的引物包括:
rb1-gRNA-F:TAATACGACTCACTATAGGGTGCATGGAGAATATGGGAGAGTTTTAGAGCTAGAAATAGC;
nf1-gRNA-F:TAATACGACTCACTATAGGGGCGCACAAGCCCGTGGAATGTTTTAGAGCTAGAAATAGC;
tp53-gRNA-F:TAATACGACTCACTATAGGGTGATTGTGAGGATGGGCCTGGTTTTAGAGCTAGAAATAGC;
gRNA-R:AGCACCGACTCGGTGCCAC;
所述gRNA-R为三个gRNA合成的通用下游引物。
在本发明的一些实施例中,步骤2)中,PCR扩增GFAP启动子时,采用的引物如下:
gfap-F:CTCGAGGTAAGGACTGAGGTGATG;
gfap-R:GTCGACAGGAACGCTGGGACTCCA。
在本发明的一些实施例中,步骤2)中,标记基因mCherry的引物如下:
mCherry-F:GGTGAGCAAGGGCGAGGAGGATAA;
mCherry-R:TTGTACAGCTCGTCCATGCCGCCGG。
在本发明的一些实施例中,步骤2)中,采用的质粒为Cas9-pXT7质粒。
在本发明的一些实施例中,步骤4)中,获得单敲斑马鱼纯合体F3的步骤如下:选择生殖细胞中表达红色荧光的嵌合体F0代,培养至成鱼,剪尾T7E1检测基因敲除情况,将基因被敲除的F0代和野生型斑马鱼进行杂交,后代中如果仍然有荧光且基因被敲除的个体,属于杂合体F1,将杂合体F1的单个个体与野生型斑马鱼再次进行杂交,后代中仍然有荧光且基因被敲除的个体为杂合体F2,由于杂合体F2来自同一个父母(杂合体F1和野生型),因此插入的荧光片段在基因组中的位置是一样的,将杂合体F2中的雌鱼和雄鱼进行杂交,在杂交得到的后代中,筛选得到GFAP启动子启动特定荧光蛋白表达且组织特异性基因敲除的斑马鱼的纯合体F3,运用T7E1检测获得纯合敲除基因型斑马鱼。
在本发明的一些实施例中,步骤5)中,将单基因敲除的纯合斑马鱼进行两两杂交,获得双基因敲除的纯合斑马鱼,再将双基因敲除的斑马鱼与另一单基因敲除的纯合斑马鱼杂交,获得多基因敲除的斑马鱼胶质瘤模型。
如上所述,本发明的基因敲除载体及其斑马鱼胶质瘤模型,具有以下有益效果:本发明利用CRISPR/CAS9技术,靶向敲除rb1、nf1和tp53基因,建立的转基因诱导恶性胶质瘤斑马鱼模型,可以通过实时荧光观察恶性胶质瘤的发生、肿瘤诱导血管生成、胶质瘤干细胞发生过程,并通过分子生物学技术探讨不同遗传背景条件下胶质瘤的发病机制差异。本发明利用GFAP启动子对这三种基因的表达进行控制,使其在神经系统中特异性表达。这一模型所诱导的恶性胶质瘤与人类胶质瘤在发生机制上更为类似,同时利用单(多)基因敲除分别诱导的恶性胶质瘤将为阐释不同遗传背景的胶质瘤患者发病机制建立多样性的转基因胶质瘤斑马鱼模型,从而为恶性胶质瘤的个性化诊疗提供有利的研究工具。
附图说明
图1A和图1B显示为本发明实施例中与胶质瘤发生最为相关的三个信号通路,图1A为RTK/PI3K/Akt信号通路,图1B为p53信号通路和Rb信号通路;
图2显示为本发明实施例中基因rb1、nf1和tp53打靶位点T7E1检测的琼脂糖凝胶电泳图,两个白色尖头表示被T7E1酶切开的片段大小,M代表Marker,con代表对照组;
图3显示为本发明实施例中基因rb1、nf1和tp53打靶位点测序结果;
图4显示为本发明实施例中转座重组载体GFAP-CAS9-mCherry构建的菌落PCR结果;
图5显示为本发明实施例中构建成功的转座重组载体GFAP-CAS9-mCherry-U6-rb1;
图6显示为本发明实施例中构建成功的转座重组载体GFAP-CAS9-mCherry-U6-nf1;
图7显示为本发明实施例中构建成功的转座重组载体GFAP-CAS9-mCherry-U6-tp53;
图8显示为本发明实施例中F0代斑马鱼剪尾筛选PCR结果,P为阳性对照,WT为野生型对照,红色字体代表阳性结果,M为Marker;
图9显示为本发明实施例中F0代斑马鱼荧光筛选结果;
图10显示为本发明实施例中F1代剪尾T7E1检测三个基因敲除结果,M为Marker,con为对照组,g1、g2为实验组;
图11显示为本发明实施例中4个月大的纯合双敲斑马鱼的成瘤结果图;
图12显示为本发明实施例中三敲斑马鱼的畸形结果图。
具体实施方式
以下通过特定的具体实例说明本发明的实施方式,本领域技术人员可由本说明书所揭露的内容轻易地了解本发明的其他优点与功效。本发明还可以通过另外不同的具体实施方式加以实施或应用,本说明书中的各项细节也可以基于不同观点与应用,在没有背离本发明的精神下进行各种修饰或改变。
须知,下列实施例中未具体注明的工艺设备或装置均采用本领域内的常规设备或装置;所有压力值和范围都是指绝对压力。
本实施例结合斑马鱼模型的优势,如体外受精和发育,胚胎出生后保持透明等,最终可以较好地解决胶质瘤转基因小鼠无法克服的困难。利用荧光显微镜,我们可以在早期实时观察在细胞水平上胶质瘤发病机制,同时还可以研究肿瘤为环境在胶质瘤发生过程中所起的作用,以及胶质瘤诱导血管生成的分子机制研究。
一.打靶位点的选择
本发明中我们选择的基因均为能诱发脑胶质细胞瘤的主要基因,分别为rb1,nf1和tp53。根据CRISPR/CAS9的编辑特点,位点一般为紧邻NGG特征序列之前的20bp序列,在chopchop网站上确认打靶序列。
二.构建重组转座载体相关元件的选择
本发明中实现转基因的技术包括CRISPR/CAS9基因编辑技术、Tol2技术、分子克隆技术。本发明的实施例中,具体是将红色荧光蛋白加入重组质粒中,从而将载体插入待处理模式生物(例如斑马鱼)的基因组中,实现稳定表达。
此外,本发明所选择的启动子为胶质细胞特异性表达启动子GFAP,由于这几种基因广泛存在于斑马鱼体内,通过直接敲除极可能会导致斑马鱼早期胚胎致死。因此,利用GFAP启动子对这三种基因的表达进行控制,使其在神经系统中特异性表达。
三.基因整合的方法与鉴定
把构建好的重组转座载体与Tol2mRNA通过显微注射同时注射到待处理斑马鱼的受精卵中,等待这些受精卵发育成幼鱼。鱼体透明,目的序列整合到鱼的基因组之后,鱼会在特定位置显示出特定荧光。将这些鱼收集并培育养大,得到gfap启动子特异性敲除的斑马鱼,定义为嵌合体F0代。
四.获得单基因稳定敲除的子代
选择生殖细胞中表达红色荧光的嵌合体F0代,待养至2个月大,剪尾T7E1检测基因敲除情况,将基因被敲除的F0代和野生型进行杂交,后代中如果仍然有荧光且基因被敲除的个体,属于杂合体F1。将这些杂合体F1的单个个体与野生型再次进行杂交,它们的后代仍然有荧光且基因被敲除的是杂合体F2,由于杂合体F2来自同一个父母(杂合体F1和野生型),因此,插入的荧光片段在基因组中的位置是一样的。将杂合体中的雌鱼和雄鱼进行杂交,在杂交得到的后代中,有1/4的概率得到GFAP启动子启动特定荧光蛋白表达且组织特异性基因敲除的斑马鱼的纯合体F3。运用T7E1检测获得纯合敲除基因型斑马鱼。
五.获得双(多)基因稳定敲除的子代
将单基因敲除的纯合斑马鱼进行两两杂交,获得双基因敲除的纯合斑马鱼,再将双基因敲除的斑马鱼与剩余单基因敲除的纯合斑马鱼杂交,获得多基因敲除的纯合斑马鱼。
实施例1
建立斑马鱼胶质瘤模型
步骤1:构建打靶序列的gRNA序列
首先在NCBI(美国国家生物技术信息中心)的网站上查到斑马鱼的rb1nf1和tp53三个基因的CDs序列。在chopchop网站上查找靶位点序列,锁定的三个基因的目标序列分别为
rb1:TGCATGGAGAATATGGGAGA;
nf1:GGCGCACAAGCCCGTGGAAT;
tp53:TGATTGTGAGGATGGGCCTG。
然后,为构建打靶序列gRNA,合成以下引物:
rb1-gRNA-F:TAATACGACTCACTATAGGGTGCATGGAGAATATGGGAGAGTTTTAGAGCTAGAAATAGC
nf1-gRNA-F:TAATACGACTCACTATAGGGGCGCACAAGCCCGTGGAATGTTTTAGAGCTAGAAATAGC
tp53-gRNA-F:TAATACGACTCACTATAGGGTGATTGTGAGGATGGGCCTGGTTTTAGAGCTAGAAATAGC
gRNA-R:AGCACCGACTCGGTGCCAC
其中,gRNA-R为三个gRNA合成的通用下游引物。
以带有gRNA骨架的质粒(中科院重庆绿色智能研究院环境健康中心)为模板,以终浓度为10μM的上游和下游引物扩增gRNA的DNA序列。
反应体系如表1所示:
表1
PCR程序设计:
第一步:95℃2min;
第二步:95℃20s;
第三步:55℃20s;
第四步:72℃10s;
第五步:返回到第二步,循环35次;
第六步:72℃10min;
反应结束。
将PCR所得产物进行琼脂糖凝胶电泳检测,在1%的琼脂糖凝胶电泳上加入10%的加样缓冲液,混匀后,加入琼脂糖凝胶的样孔中,150V电压15min电泳。
切胶回收步骤(天根试剂盒):在紫外的照射下,对比参照梯状条带(ladder),将目的条带(100bp)切下(割胶尽可能的小,提高后续回收效率),向胶块中加入等倍体积溶液PN(如果凝胶重为0.1g,其体积可视为100μL,则加入100μL PN溶液),50℃水浴放置,其间不断温和地上下翻转离心管,以确保胶块充分溶解;柱平衡步骤:向吸附柱CA2中(吸附柱放入收集管中)加入500μL平衡液BL,12,000rpm离心1min,倒掉收集管中的废液,将吸附柱重新放回收集管中。将上一步所得溶液加入一个吸附柱CA2中(吸附柱放入收集管中),室温放置2min,12,000rpm离心1min,倒掉收集管中的废液,将吸附柱CA2放入收集管中。向吸附柱CA2中加入600μL漂洗液PW,12,000rpm离心1min,倒掉收集管中的废液,将吸附柱CA2放入收集管中。12,000rpm离心2min,尽量除尽漂洗液,将吸附柱CA2置于室温放置数分钟,彻底地晾干将吸附柱,将CA2放到一个干净离心管中,向吸附膜中间位置悬空滴加20μLddH2O,室温放置2min。12,000rpm离心2min收集DNA溶液。
步骤2:体外转录及RNA回收
将切胶纯化的产物转录成RNA,用mMessagemMachine Kit(Ambion公司)进行体外转录;
反应体系如表2所示:
表2
| 用量 | 组分 |
| 600ng | DNA模板 |
| 2μL | 10×缓冲液 |
| 1μL | 10mM NTP Mix |
| 1μL | 酶混合液 |
| 至20μL | 无核酸酶水 |
将上述混合液放入PCR仪中37℃,3h进行转录。
将RNA产物加入祛DNA酶,PCR仪中37℃15min。
RNA的纯化(天根试剂盒):在RNA样品中加入RNase-Free水补足至100μL,加入350μL溶液RK,充分混匀。加入250μL无水乙醇,充分混匀,立即进行下一步。将上一步所得溶液和沉淀一起转入吸附柱CR2中,12,000rpm离心30sec,弃掉收集管中的废液。向吸附柱CR2中加入500μL已加入乙醇的漂洗液RW,室温放置2min后,12,000rpm离心30sec,弃废液,将CR2放入收集管中。12,000rpm离心5min,去除残余液体。将吸附柱CR2转入一个新离心管中,加14μLRNase-Free水,室温放置2min后,12,000rpm离心2min。得到gRNA放于-80℃保存。
步骤3:CAS9的体外转录和RNA回收
体外转录:
将Cas9-pXT表达载体线性化处理。步骤如下:取800ng Cas9-pXT7质粒(购自湖北武汉水生生物研究所),加入XbaI内切酶1μL,10X缓冲液2μL,其余体积是ddH20,配成20μL的酶切体系,放在37℃的的水浴锅内酶切2小时。
反应结束后,加入1/20体积0.5M EDTA,1/10体积的5M NH4acetate,2倍体积的无水乙醇。混匀,放在-20℃冷冻20分钟后取出。放在小离心管中,最高转速离心15分钟。吸取并丢弃上清液,晾干。加入ddH20溶解,保证最终浓度在0.5-1μg/μL。产物中加入浓度为150μg/mL的蛋白酶K和0.5%SDS,在50℃水浴中反应30分钟。将反应产物通过胶回收试剂盒的柱子回收DNA(全式金)。首先,混合3倍体积GSB溶液,加入胶回收柱子,静置1分钟。12,000rpm离心1min。加入500μL漂洗液,14000g离心1分钟。加入45μL水洗脱,12,000rpm离心一分钟,得到线性化产物。
用mMessagemMachine Kit(Ambion公司)进行体外转录,步骤如下。
按照表3所示配方:
表3
| 用量 | 组分 |
| 10μL | 2×NTP/CAP |
| 2μL | 10×缓冲液 |
| 0.1μg-1μg | 线性模板DNA |
| 2μL | 酶混合液 |
| 至20μL | 无核酸酶水 |
将上述混合液放入PCR仪中37℃,3h进行转录。
将RNA产物加入祛DNA酶,PCR仪中37℃15min。
RNA的纯化(天根试剂盒):在RNA样品中加入RNase-Free水补足至100μL,加入350μL溶液RK,充分混匀。加入250μL无水乙醇,充分混匀,立即进行下一步。将上一步所得溶液和沉淀一起转入吸附柱CR2中,12,000rpm离心30sec,弃掉收集管中的废液。向吸附柱CR2中加入500μL已加入乙醇的漂洗液RW,室温放置2min后,12,000rpm离心30sec,弃废液,将CR2放入收集管中。12,000rpm离心5min,去除残余液体。将吸附柱CR2转入一个新离心管中,加14μLRNase-Free水,室温放置2min后,12,000rpm离心2min。得到gRNA放于-80保存。
步骤4:显微注射受精卵以及打靶效率检测
1.收卵:
在喂完晚餐后30分钟后,在配鱼的专用鱼缸中,加入雌雄比2∶1放置不多于八条的斑马鱼,用隔板将雌雄分开,放入三分之二的养鱼水。第二天早晨抽去隔板,雄鱼开始追逐雌鱼,一般在15分钟雌鱼开始排卵,雄鱼将精子排入水中使卵受精,收集卵到平板培养皿中,去除死卵和杂物,用养鱼水洗涤几次,等待注射。
2.注射:
制备注射皿,30mL的2%琼脂糖加热融化,倒入直径10cm的玻璃皿中,将模具轻轻覆盖于表面,待胶凝固后,移走模具。加入少量养鱼水,保持界面湿润。准备注射针,将外径为1.02mm内径0.58mm的玻璃毛细管用拉针仪拉成针形。
待受精卵排出后,再过约10分钟卵膜膨胀,随后数分钟内细胞形态变得规整,此时可以开始注射。用无齿镊在体视镜最高倍放大率下将针头折断少许,尽量断成斜切面。用微量上样吸头吸取1-5μL胚胎纤维注射液从针尾穿入注射针上样,随后将注射针插入持针器中固定。将胚胎清洗后,放入注射模具中,排列成行,吸去多余的液体,使液面刚刚没过鱼卵。注射时,注射针从胚胎动物极插入到细胞质中和从卵黄中穿过抵达胞质中。将Cas9-pXT7载体转录出的Cas9mRNA(稀释至300ng/μL)和gRNA(20ng/μL)共同打入斑马鱼的单细胞期受精卵中。每枚卵注射,Cas9mRNA量为25pg,gRNAmRNA量为25pg的混合物。用针尖拨动注射凹槽中的胚胎使细胞质方向与针尖方向一致或者相对,与水平面约成45度下针,扎入到位后踩动踏板注射,略保持后迅速退针,整个过程注意手不要抖动。
注射结束后,将胚胎移至含有养鱼水的10cm培养皿中,再转移到28.5℃的环境中培养,等待孵化。这段时间需要定期检测,去除死胚和脱下的卵膜,并更换养鱼水。大约到4-5天时,胚胎可以进食草履虫,此时应转移至小鱼喂养盒中。幼鱼12天起可以开始用草履虫和卤水混合喂养,注意及时清理鱼缸,保持水质良好。待幼鱼全部吃卤水时(此时幼鱼的腹部呈红色),可转入鱼房喂养。
3.打靶效率检测
提取DNA
显微注射24h后,收取对照组和注射组各30颗鱼卵,用CTAB法提取DNA,每组加入100μL的裂解液(100mMTris-Hcl pH 8.5,0.5M EDTA,10%SDS,5M NaCl,20mg/ml蛋白酶K)放入55℃水浴1h。用氯仿和异丙醇抽提后,用75%的乙醇清洗,保存于4℃或用于以下实验。
PCR扩增
设计以下引物,扩增含有打靶位点序列的DNA片段。
T-rb1-F:ACCATGTCTGTCAACTGTTGTT
T-rb1-R:TACACCACTCCTGAGAGGCAA
T-nf1-F:AACTTCCGGTGGTGTGTCAT
T-nf1-R:CAGTGCAAGCCCAAAACCAC
T-tp53-F:ACATGAAATTGCCAGAGTATGTGTC
T-tp53-R:TCGGATAGCCTAGTGCGAGC
以上述提取的DNA为模板,以终浓度为10μM的上游和下游引物PCR扩增DNA序列。
反应体系如表4所示:
表4
PCR程序设计:
第一步:95℃2min;
第二步:95℃20s;
第三步:55℃20s;
第四步:72℃10s;
第五步:返回到第二步,循环35次;
第六步:72℃10min;
反应结束。
将PCR所得产物进行琼脂糖凝胶电泳检测,在1%的琼脂糖凝胶电泳上加入10%的加样缓冲液混匀后,加入琼脂糖凝胶的样孔中,150V电压15min电泳。若有条带则进行以下实验,若无条带则重新设计引物重新PCR
T7E1检测
三个基因扩增的片段大小分别为rb1:406bp;nf1:420bp;tp53:336bp。
将三种PCR产物以及对照各取8μL,在PCR仪里进行退火,然后各加入0.5μL的T7E1酶和1μL T7E1buffer的混合液,37℃25min。反应结束后,将产物进行琼脂糖凝胶电泳检测,在2%的琼脂糖凝胶电泳上加入10%的加样缓冲液混匀后,加入琼脂糖凝胶的样孔中,150V电压15min电泳。结果如图2所示。箭头表示被T7E1酶切开的突变序列。
测序检测突变效率
将上述产物连入pMDTM18-T(TAKARA)载体后送金唯智公司测序,结果如图3所示。黑色字母代表原始基因组序列,红色代表打靶序列,绿色是PAM区,黄色是突变区域。
步骤5:构建转座重组载体
1.插入GFAP启动子序列
(1)PCR扩增GFAP启动子序列
用以下引物在斑马鱼基因组中PCR扩增GFAP启动子;
gfap-F:CTCGAGGTAAGGACTGAGGTGATG
gfap-R:GTCGACAGGAACGCTGGGACTCCA
反应体系如表5所示。
表5
| 用量 | 组分 |
| 12.5μL | PrimeSTAR Max Premix(2×) |
| 1μL | 2A-mCherry-gfap-F |
| 1μL | 2A-mCherry-gfap-R |
| 1μL | 模板 |
| 9.5μL | ddH2O |
| 25μL | 总计 |
PCR程序设计:
第一步:98℃5min;
第二步:98℃10s;
第三步:62℃5s;
第四步:72℃1min;
第五步:返回到第二步,循环35次;
第六步:72℃10min;
反应结束。
电泳:将PCR产物加入10%的加样缓冲液混匀,加入配好的1%的琼脂糖凝胶的样槽中,150V恒压15min电泳。把琼脂糖凝胶放在紫外照射下,对比参照梯状条带(ladder),条带应在7400bp左右。序列为SEQ ID NO.2所示。
采用购自天根的胶回收试剂盒,进行胶回收,步骤如下:向胶块中加入等倍体积溶液PN(如果凝胶重为0.1g,其体积可视为100μL,则加入100μL PN溶液),50℃水浴放置,其间不断温和地上下翻转离心管,以确保胶块充分溶解。柱平衡步骤:向吸附柱CA2中(吸附柱放入收集管中)加入500μL平衡液BL,12,000rpm离心1min,倒掉收集管中的废液,将吸附柱重新放回收集管中。将上一步所得溶液加入一个吸附柱CA2中(吸附柱放入收集管中),室温放置2min,12,000rpm离心1min,倒掉收集管中的废液,将吸附柱CA2放入收集管中。向吸附柱CA2中加入600μL漂洗液PW,12,000rpm离心1min,倒掉收集管中的废液,将吸附柱CA2放入收集管中。12,000rpm离心2min,尽量除尽漂洗液,将吸附柱CA2置于室温放置数分钟,彻底地晾干将吸附柱,将CA2放到一个干净离心管中,向吸附膜中间位置悬空滴加20μLddH2O,室温放置2min。12,000rpm离心2min收集DNA溶液。
(2)载体骨架酶切
采用XholI和SalI限制性内切酶对pTol2-CAS9-mCherry-gRNA-U6载体骨架(购自南京尧顺禹生物公司)进行双酶切,50μL体系为:5μg载体,XholI和SalI限制性内切酶各5μL,酶切buffer 5μL,水补足50μL。37℃2h后进行胶回收,步骤同上。
(3)连接
将GFAP胶回收产物和载体胶回收产物进行连接反应。在10μL的连接体系中加入500ng的GFAP胶回收产物,100ng的线性化载体的产物,2μL T4连接buffer,0.1μL T4连接酶,水补足10μL体系,混匀后22℃恒温3h。
(4)转化涂板,鉴定阳性克隆
连接产物转化和涂板:将连接产物加入感受态细胞中(在感受态细胞刚刚解冻时加入连接产物),冰浴30min,加入到42℃水浴锅中30s,立即至于冰上2min,加入800μL的LB培养基,37℃摇床内复苏1h后取出,6000rpm离心3min,弃去500μL上清,将余下部分混匀后涂板,涂在Amp+抗性的平板上,待液体完全干为止,平板放在37℃培养箱中过夜。
鉴定阳性克隆:待菌落长出来后,用10μL的白枪头挑单菌落,在10μL超纯水中混匀,取1μL做PCR模板,加入gfap-F和gfap-R两引物,62℃进行PCR反应35个循环。取PCR产物,加入10%的加样缓冲液混匀,加入配好的1%的琼脂糖凝胶的样槽中,150V恒压15min电泳。把琼脂糖凝胶放在紫外照射下,对比参照梯状条带(ladder),在7400bp左右有条带的菌落,是阳性菌落,如图4所示。加入5ml带5μLAmp+的培养基摇菌,37℃过夜后提质粒。
提质粒的步骤如下(天根试剂盒):向吸附柱CP3中,加入500μL平衡液BL,12,000rpm离心1min,倒掉收集管中的废液,将吸附柱重新放回收集管中。取5mL过夜培养的菌液,加入离心管中,12,000rpm离心1min,尽量吸除上清,向留有菌体沉淀的离心管中加入250μL溶液P1,用涡旋振荡器彻底悬浮细菌沉淀。向离心管中加入250μL溶液P2,温和地上下翻转6-8次使菌体充分裂解。向离心管中加入350μL溶液P3,立即温和地上下翻转6-8次,充分混匀,此时将出现白色絮状沉淀。12,000rpm离心10min。将上一步收集的上清液用移液器转移到吸附柱CP3中,12,000rpm离心1min,倒掉废液,将吸附柱CP3放入收集管中,向吸附柱CP3中加入600μL漂洗液PW,12,000rpm离心1min,倒掉收集管中的废液,将吸附柱CP3放入收集管中12,000rpm离心2min,目的是将吸附柱中残余的漂洗液去除。将吸附柱CP3开盖,置于室温放置数分钟,以彻底晾干吸将吸附柱CP3置于一个干净的离心管中,向吸附膜的中间部位滴加35μL ddH2O静置2min,12,000rpm离心2min将质粒溶液收集到离心管中。
金唯智公司测序,比对序列,正确的即为构建成功的重组载体GFAP-CAS9-mCherry。
2.插入打靶序列构建转座重组载体GFAP-CAS9-mCherry-U6-gRNA
(1)用步骤1中已经确认的三个打靶序列合成以下引物
rb1-F:CACCTGCATGGAGAATATGGGAGA
rb1-R:AAACTCTCCCATATTCTCCATGCA
nf1-F:CACCGGCGCACAAGCCCGTGGAAT
nf1-R:AAACATTCCACGGGCTTGTGCGCC
tp53-F:CACCTGATTGTGAGGATGGGCCTG
tp53-R:AAACCAGGCCCATCCTCACAATCA
以上上下游引物稀释成5μM 10μL体系95℃进行退火后备用。
(2)GFAP-CAS9-mCherry载体酶切
GFAP-CAS9-mCherry载体用BbsI限制性内切酶进行酶切,50μL体系为:5ug载体,BbsI限制性内切酶5μL,酶切buffer 5μL,水补足50μL。37℃2h后进行胶回收,步骤同上。
(3)连接
将GFAP-CAS9-mCherry胶回收产物和退火产物进行连接反应。在10μL的连接体系中加入100ng的GFAP胶回收产物,500ng的退火产物,2μL T4连接buffer,0.1μL T4连接酶,水补足10μL体系,混匀后22℃恒温1h。
(4)转化涂板,送测序
连接产物转化和涂板:将连接产物加入感受态细胞中(在感受态细胞刚刚解冻时加入连接产物),冰浴30min,加入到42℃水浴锅中30s,立即至于冰上2min,加入800μL的LB培养基,37℃摇床内复苏1h后取出,6000rpm离心3min,弃去500μL上清,将余下部分混匀后涂板,涂在Amp+抗性的平板上,待液体完全干为止,平板放在37℃培养箱中过夜,提质粒,金唯智公司测序,比对序列,正确的即为构建成功的重组载体GFAP-CAS9-mCherry-U6-rb1(图5),GFAP-CAS9-mCherry-U6-nf1(图6),GFAP-CAS9-mCherry-U6-tp53(图7)。
步骤6.显微注射
收卵:
在喂完晚餐后30分钟后,在配鱼的专用鱼缸中,加入雌雄比2:1放置不多于八条的斑马鱼,用隔板将雌雄分开,放入三分之二的养鱼水。第二天早晨抽去隔板,雄鱼开始追逐雌鱼,一般在15分钟雌鱼开始排卵,雄鱼将精子排入水中使卵受精,收集卵到平板培养皿中,去除死卵和杂物,用养鱼水洗涤几次,等待注射。
注射:
制备注射皿,30mL的2%琼脂糖加热融化,倒入直径10cm的玻璃皿中,将模具轻轻覆盖于表面,待胶凝固后,移走模具。加入少量养鱼水,保持界面湿润。准备注射针,将外径为1.02mm内径0.58mm的玻璃毛细管用拉针仪拉成针形。
受精卵排出后,再过约10分钟卵膜膨胀,随后数分钟内细胞形态变得规整,此时可以开始注射。用无齿镊在体视镜最高倍放大率下将针头折断少许,尽量断成斜切面。用微量上样吸头吸取1-5μL胚胎纤维注射液从针尾穿入注射针上样,随后将注射针插入持针器中固定。将胚胎清洗后,放入注射模具中,排列成行,吸去多余的液体,使液面刚刚没过鱼卵。
注射时,注射针从胚胎动物极插入到细胞质中和从卵黄中穿过抵达胞质中。分别将三个转座重组载体
GFAP-CAS9-mCherry-U6-rb1,GFAP-CAS9-mCherry-U6-nf1,GFAP-CAS9-mCherry-U6-tp53
(30ng/μL)和转座Tol2mRNA(50ng/μL)共同打入斑马鱼的单细胞期受精卵中。用针尖拨动注射凹槽中的胚胎使细胞质方向与针尖方向一致或者相对,与水平面约成45度下针,扎入到位后踩动踏板注射,略保持后迅速退针,整个过程注意手不要抖动。
注射结束后,将胚胎移至含有养鱼水的10cm培养皿中,再转移到28.5℃的环境中培养,等待孵化。这段时间需要定期检测,去除死胚和脱下的卵膜,并更换养鱼水。大约到4-5天时,胚胎可以进食草履虫,此时应转移至小鱼喂养盒中。幼鱼12天起可以开始用草履虫和卤水混合喂养,注意及时清理鱼缸,保持水质良好。待幼鱼全部吃卤水时(此时幼鱼的腹部呈红色),可转入鱼房喂养。
步骤7:嵌合体F0的筛选与鉴定
1.分子生物学验证
(1)待幼鱼长至2个月大时剪尾检测荧光表达情况,用PCR分子生物学手段,证实基因组中是否有mCherry的表达。引物设计如下:
mCherry-F:GGTGAGCAAGGGCGAGGAGGATAA
mCherry-R:TTGTACAGCTCGTCCATGCCGCCGG
反应体系如表6所示。
表6
PCR程序设计:
第一步:94℃3min;
第二步:94℃5s;
第三步:57℃15s;
第四步:72℃10s;
第五步:返回到第二步,循环35次;
第六步:72℃10min;
反应结束。
其中,PCR模板来源于斑马鱼的基因组。正向和反向引物由金唯智生物公司合成,其被稀释为10μL的工作浓度。Taq DNA Polymerase kit购自于全式金生物公司。总的PCR体积为20μL。反应结束后,PCR管内产物放在4℃冰箱保存或直接进行下一步。
电泳:取PCR产物,加入10%的加样缓冲液(loading buffer)混匀,加入配好的1%的琼脂糖凝胶的样槽中,150V恒压15min电泳。把琼脂糖凝胶放在紫外照射下,对比参照梯状条带(ladder),测定产物条带应在300bp左右(图8)。将有此条带的的个体确定为F0代。
2.荧光筛选
荧光蛋白在注射24h后出现表达,在荧光显微镜下观察幼鱼,挑出表达红色荧光蛋白的幼鱼,将幼鱼放在10cm的皿中,再次检查是否都有荧光,将没有荧光的幼鱼丢弃,剩下的就是嵌合体F0(图9)。
步骤8:筛选纯合单基因敲除的斑马鱼
将得到的嵌合体F0和野生型进行杂交,后代中仍然带有红色荧光特性的个体属于杂合体F1,杂合体F1代其全身基因组都带有转座的外源基因,所以剪尾检测的结果也可以遗传,所以在杂合子F1代长至2个月大时剪尾检测基因的敲除情况。
取单条鱼剪尾后用CTAB法提取DNA,如步骤4所述,之后根据步骤4的引物和PCR程序进PCR扩增和T7E1检测,结果如图10所示。筛选出能被T7E1酶酶切的DNA所对应的个体,此F1代为单基因敲除的杂合子。
用此F1代进行互交,其中有1/4为纯合子,同样用PCR和T7E1检测筛选出纯合子。即得到单基因敲除纯合子斑马鱼。
步骤9:双(多)基因敲除的斑马鱼胶质瘤模型的获得
用纯合的单基因敲除斑马鱼进行两两互交就能够得到双基因敲除斑马鱼,再用双基因敲除斑马鱼与另一单基因敲除斑马鱼杂交就得到多基因敲除斑马鱼胶质瘤模型。其中,如图11所示,双基因敲除斑马鱼在4个月时成瘤;如图12所示,三基因敲除的模型在出生后基本畸形。
上述实施例仅例示性说明本发明的原理及其功效,而非用于限制本发明。任何熟悉此技术的人士皆可在不违背本发明的精神及范畴下,对上述实施例进行修饰或改变。因此,举凡所属技术领域中具有通常知识者在未脱离本发明所揭示的精神与技术思想下所完成的一切等效修饰或改变,仍应由本发明的权利要求所涵盖。
SEQUENCE LISTING
<110> 汕头大学医学院
<120> 一种基因敲除载体及其斑马鱼胶质瘤模型
<130> PCQST176837
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 17534
<212> DNA
<213> Artificial
<220>
<223> 基因敲除载体
<400> 1
gtaaggactc gaggtgatgc acagtgttgg gtatgttact ttcaataagt tattctttgc 60
taattattag tcatttgaat tgtattgaaa ttacattttt agttactttg cctaaaaaaa 120
aacttgataa gtaatcgaat tacatacttg aagtccacat aaatctcatt cattcattcc 180
ttctcttttc gacttagtcc ctttattaat caggggtttc tacagcggaa cgaacctcat 240
atgtttcaat ttagtgacta ttttttataa attattgaca atgtttttgt tgcttgttca 300
aactacttat ttaaaatgag ctgaaactgc acaattattg atatttcatt ggaacagctt 360
aatttttttt atgtttaatc cacttaaata aaattccaat tatataatat tccaattata 420
aagttactta atcaatttgt attaggacaa tatgaatgaa ttgtgtggaa ccctgcattt 480
tttacagtga acctttcctt gtttcttaaa catgggtgat tttcggagaa ataaaatttg 540
acaatatctg aaatgtaaaa agaaaatatt cagttactct gcctttctaa atgcatagtt 600
tatattatca tcagagttgt aaagtaacta gttacaaata ctcaaattac tgtaattgag 660
tagttttttt caggaattgt aatttactaa gtagctaaaa aatgtgtact tttactttcc 720
cttgagtaca ttattaatgc tgtaacggta cttttactcc actactttcc ttcagcctgc 780
actcactact ttgttttatc ttgtctatga ggattagaaa aatcaatcct gtgattccaa 840
tcaaatcgca catccaaagt ctttacaaaa gcattttgtt tggatgtgaa aatcgggttg 900
atgtcagaac tcaatgtcag cccaacgtca atgtccaacc taaaatcaac ctaatatcaa 960
cgtctaatga tgttacagct tgacgttgtg tgggcgttac cattatttgt cagacattgg 1020
attttagttg ccatacctga taaataaatg tcagtatttg atgtccgtat gatcttggat 1080
ttagatgttg gctcgacatt ggattttggt cacctgacat aacaacctaa atctatccta 1140
ataataacgt cttatgacgt tgtgtgccaa ccatttttgt ttattaaaaa tttatataaa 1200
catttacaat aatatattat ccatgtgatt taatagaaat gttatttgtt ttttttctcc 1260
cccatatttc tgaatgactt aaagctttta ttatcaggat aaggttgtgg tttttatttt 1320
ttgcttgcta acttcaattg ctattgcatt tacatttatg caaatgggga gacgcggtgg 1380
gtcagttggc gtttctgtgt ggagtttgca tgttctcccc gtgttcgcgt gggttttctc 1440
tgggtgctct ggtttcccct aaagacatgt agtataggtg aattgggtaa gctaaattgt 1500
ccgtagtgtg tatgtgtgaa tgtatggatg ttttcctgtg atgggttgca gctgaaaggg 1560
catccgctgt gtaaaacata tgctggataa gttggcaatt catttcgctg tggtaacccc 1620
agattaatat cggaactacg ccaaaaagaa aatgaatgaa tgagtgaatt aatgcaaatg 1680
gctcatcctt ccacctaatt ccagtgcctt gcattgcatt caagctctac aattaatcag 1740
ttcctttatt ttcactttcc aaactgaatc caacaactca tgaggacccc agggtgcctt 1800
gatttaccag tgtcatgatg aacacaatct accccacttt aacccactcg tcaacataaa 1860
tactccctta aagggtgtac ttgtgtctga gtagaagtgt ctgctgggtt ggaggtgtcg 1920
cacattccag gacacgtcaa gaagaacgct aagagcaaca ggagaacaat gtcacaaaaa 1980
aggtcaaaga aacgccatcc attagccagc tttataaaca gctgtctcgt ggctaaagaa 2040
gttctcaaga ataaccaacc ttgcattttt ccacattagt tttacaccgc agcaaagtca 2100
ccatgtggat ttatagcatc caaaccccat tttcaatgag aggcttcaca tttctcgctc 2160
tcattcaatc ccacactgcc tctcttttca gactaaatcc tgataggatg agtggtatgg 2220
gggcggggag ggggcacaat acctcagtcc agcttccaca aagactcaac acacccatgc 2280
agatgtcctg ttgttgggga agtgcatttg taaccaaatt tcaaactttc aactttcatt 2340
tgaagcagtg gagactgctc cattcctatt caagatcaat ttattgaaat atgacaacat 2400
ttagaataac tttgttatat gttattatgt tttataatgc aattttgttt ctgtgacata 2460
cattttttta tttagtgcag tcttcagagc cacaggaacc ttgagaatca ttctaattat 2520
gatttgctac tcgaaaaaca tttttcatca tcaataataa gaaattaaaa cggtatacat 2580
atagatgttt agtataacag ttcttagtag tttaaaagaa catttgtaac aacattccaa 2640
ccttttaata actttagcct tgcttacatt tctaaaggag agccttccag ctgtttttct 2700
gaacccagtg atgaatgtaa agttcttaaa accaagttct aagaatgttt taatgattac 2760
atttaaccca atttcaagcc aaatttccta taccacgagt aaaatatagt tataattagg 2820
atagatcttt ggtaaaataa gatacaattt taagatttga atttaaaagt agctaaattg 2880
tttttttatg acagaacttt taagtttata gaatattaat acaggacaaa acttgtaaat 2940
gtatttaatt tcctatgaat atttgataaa atataaatga catctatatg taaattcatg 3000
aaccatgact cttatgaatt atcagtgcac aaattatgtt tgatgcacac ttaaggtcaa 3060
aagtttaggg tcagtttatt ttttttttta tttttaattt tatttaataa tttaaataaa 3120
attattctgt tcatcaaggc acatttatta aatgtaacaa taaattgtta aatacttatt 3180
aaatatttat tttttactta ttgtatgcag tttcaattga agtcattatt gcttttatta 3240
ctattaccat taataaaaat aacattaata ataataataa taataataat aattgatatt 3300
acagtgattt ctgaaggatc acgtgactga agactggagt aatgaagctg aaaactcatc 3360
atttaaatca ctggagtaaa tgattcaatt aaatgatcat ttaatgatca ttcttttgaa 3420
cagttatttt atagtgcaat aacatttcac agttttacca tttgttttgt atttttgatt 3480
caataaatgc agccttggtg agcaggagaa gcttaattta aaacatttaa aactcctact 3540
gaccccaaac ttttgaccgg tagtgtacat gtattactgt atgttcaaac tatatgcttt 3600
tattcataag tgtttctatt gctgtacatt tgactgtctg catcaggtga agtgtatgaa 3660
agagtgtgtg tttactccac cccgtgggaa agagcagtag ctgcaatgtg tgtgtgtgag 3720
tagttagtga tgcatgagtg atccactgaa ccctgtccag ccccctgctg cagctctcaa 3780
cacatcatga taggtcacct ctactgggag gctttcagca cagctctcac aactgattta 3840
tcagagagta ctctgaaatg gagaaattac tttcatatta aagagcacac acacacacac 3900
acacacacac acacacacac acacacacac acacacacac acacacacac ctagttcacc 3960
ttattaacgt ggttaagcct ttaaatgtca ctttaagctg tatagaagtg tcttgaaaaa 4020
tatctattca aatattattt actgtcatca aggaaaagat aaaataaatc agttattaga 4080
aataagtttt taaaactatt atacttagaa atgtgctgaa acaatcttcc tagaacagaa 4140
cagaaattgg ggaaaaaata aacaaaaata aataaatcta tctatctata gtgtgtataa 4200
tgtgtgtagt gagtatgttt aaaataggtc aactaatatg ttcataataa aaatacagca 4260
tcaatggttt gggtgttttt agatccaaag gtcttaaacg tggttattgc tggttgttca 4320
gttttttcta ggctctaaga aaaatcattt tagaaactgt aactgtttcc ttatccatct 4380
gaattccacc tttgggatgt agtggaacgg gagatcaact gcatgatgct atcaagtcaa 4440
tatggatcaa aatctcagga atatttccag gaccttattg aatctatgcc atgaaggatt 4500
aaggcagttc tgaaagggga aatgcggttt aacccggtaa tagcaaggtg tacctaataa 4560
agtggccggt gagtgtatat attgttattg tttcaccttc agaaatgaca tatctagaca 4620
atagtttcct ttttcttttt taattattgt acttctgtaa gattcttcaa tgttcaatgg 4680
ttttcttatg ttaaaggcgc agagctgtag ttttagtgaa gtaacagcat tccgttgacc 4740
aaagctgaca gatgaaggag agtcagttct gaccttgcag ttgtcagtca caattaagcc 4800
tggtttggtt acaagttaaa cgtagacctg cttgtggtca ggatcatcct ttaaaagaac 4860
tagatttgtt tttaacaatt tgtaaccggt gtgctctgaa gtgtcttaaa taaagcatat 4920
aggaagcaaa gcagtgaaaa atgttcctta taatctacga gcattagctt aaatgtataa 4980
acaaaataat attaattgtg tgttcagatc aaatataggt attgttacac ctaaaataaa 5040
cccattgctt taaaaaataa ttaaacacag tgtacaatat tagcatactt cctctgacat 5100
ctctaagtaa aacaagagct ttcacgattt actcactgac ccatcttaca gcacttctct 5160
gtgaatttag gccatcacaa atgctgtgcc cagttctctg actgggtttg acagtcgccc 5220
atctgtgtcc agcagtctga tgagctcatc ctctgtaaat ctggctggct gccgtgttgt 5280
tttgtgtctg tccgtgagtc tctctggcct tcatacactc ctctgctact tcatagactg 5340
ctgatgagtg cagaggccaa accattagtg cttttctttt tttttagacc tcagtaatgc 5400
acaacaatgc aaaacaagta gattgagcct tttgttcttt ggactgagca tttggttaga 5460
atagcttgaa gggatagtta gaagatattt tgaagggaaa ctaaaaacct gttaccattt 5520
gacatccaaa gaaggaaaac taatatgatt gagtggttac agatttccaa cacttttcaa 5580
catatattat tttgtgttcc actaaagaaa cagtcaaata ttatactgtc aaccaaagta 5640
ctgcacttga ctcaaaaaag ctctgcagca agttgcctct tattctaggt cgagtcaacc 5700
tttttttctc tctctctgtc ggttcattca aggttcagta aatgatgaca gaattttcag 5760
cttttatttt gggtgaacta accctttata tatttgttgt aagtttattt ttctgtatat 5820
tataaatata ttagcaacat aattctaagc tacacttgta cccaatcaag ggtcacactt 5880
tattttgatg gtatgtttgt ttgaatttaa gttacattgc atctacatgt caactaattc 5940
tcattagatt ataagaagac tgttaggttg gggttagtgt aagttgacat gtacttgcaa 6000
agtttctcag agtcagttaa atgtctgttt tgtagcagta ttaacagata ttaagcacac 6060
tgtatattaa tactcaaatg aaccgtcaaa ataaagtgtt accgtaaaaa ttatttccac 6120
atctcaaggt agctttatga ggaaagtttt ctttaagatt agtttcttcg aacaaacttg 6180
catgttaaat atgtgctcag atatggggca cacagacaaa atgtttattg gacgaataac 6240
ccctttaaca gttaaccagc attttttaaa gggatagtca gaagatattt tgaaggaaac 6300
taaaaacctg taaccattcg acaatcgaag aaggtaaaag aaatatgata gagtagttac 6360
agtttttcaa cactctttat aatatattgt ttagtattca actgaagaaa tagtcaaaca 6420
cactgtaaaa aaagttggtt taaattgact caactttcaa ctcaagtata gtacttgact 6480
tgatttaagt tgagttaact agactaaact aaaagcacta aaagcactgc ggcaagtcgc 6540
ctttcaattt taggttgagt aaattattat tatttttttt tacagttcag gttcagtaaa 6600
tgataacata attttcagtt ttgggtgaac tatcccttta tatatttgtt gtaagttaat 6660
ttttctgtaa attataaatt aattagcaaa aaagctgcac ttcttcacca ttaattaatt 6720
aatacatctc aaagtagctt tataaggaaa gttttcttta attatgtttc tttgcatgtt 6780
aaaattgtgc tcagatatgg agcacacaag caaaatgttt attggatgaa taaccccttt 6840
aacatttaac cagcatgagt tcaagtaaac aaatcaattc ctatgatttt tctgctaaac 6900
cgatataaat cagtgctgct gaagagcatg tgtgtgatgt tctcagatca gcacaaaaga 6960
gggagcgcca gtttctttta ataatgaaga attacgtaat cacctcctgt gttccctgaa 7020
accattaaac tcccagacag aacaaaactg tgactgagaa agcagagcaa ctccggagta 7080
actcagaaga tctgcaaacc aactctttag catgaggtaa gagagaatta aagtccaata 7140
tcagtgctga tgccatctca gtctctctat ttctgtgttc cagcagggta tgaataggat 7200
tttctctgac tcactgtgaa aagaggcagt caggagactg gctggacaag cacaaacaat 7260
tgcgggctca caaacacccc ctcggccttt gccctcccca tcagaccccc cctctctctt 7320
tcacccccca catcaactct ataaaaaccc agagttcacc cgcactcgat ctcattctcc 7380
tccaccatgg agtcccagcg ttcctcctcg agggatccgt cgaccatatg accggtgcca 7440
ccatggacta taaggaccac gacggagact acaaggatca tgatattgat tacaaagacg 7500
atgacgataa gatggcccca aagaagaagc ggaaggtcgg tatccacgga gtcccagcag 7560
ccgacaagaa gtacagcatc ggcctggaca tcggcaccaa ctctgtgggc tgggccgtga 7620
tcaccgacga gtacaaggtg cccagcaaga aattcaaggt gctgggcaac accgaccggc 7680
acagcatcaa gaagaacctg atcggagccc tgctgttcga cagcggcgaa acagccgagg 7740
ccacccggct gaagagaacc gccagaagaa gatacaccag acggaagaac cggatctgct 7800
atctgcaaga gatcttcagc aacgagatgg ccaaggtgga cgacagcttc ttccacagac 7860
tggaagagtc cttcctggtg gaagaggata agaagcacga gcggcacccc atcttcggca 7920
acatcgtgga cgaggtggcc taccacgaga agtaccccac catctaccac ctgagaaaga 7980
aactggtgga cagcaccgac aaggccgacc tgcggctgat ctatctggcc ctggcccaca 8040
tgatcaagtt ccggggccac ttcctgatcg agggcgacct gaaccccgac aacagcgacg 8100
tggacaagct gttcatccag ctggtgcaga cctacaacca gctgttcgag gaaaacccca 8160
tcaacgccag cggcgtggac gccaaggcca tcctgtctgc cagactgagc aagagcagac 8220
ggctggaaaa tctgatcgcc cagctgcccg gcgagaagaa gaatggcctg ttcggaaacc 8280
tgattgccct gagcctgggc ctgaccccca acttcaagag caacttcgac ctggccgagg 8340
atgccaaact gcagctgagc aaggacacct acgacgacga cctggacaac ctgctggccc 8400
agatcggcga ccagtacgcc gacctgtttc tggccgccaa gaacctgtcc gacgccatcc 8460
tgctgagcga catcctgaga gtgaacaccg agatcaccaa ggcccccctg agcgcctcta 8520
tgatcaagag atacgacgag caccaccagg acctgaccct gctgaaagct ctcgtgcggc 8580
agcagctgcc tgagaagtac aaagagattt tcttcgacca gagcaagaac ggctacgccg 8640
gctacattga cggcggagcc agccaggaag agttctacaa gttcatcaag cccatcctgg 8700
aaaagatgga cggcaccgag gaactgctcg tgaagctgaa cagagaggac ctgctgcgga 8760
agcagcggac cttcgacaac ggcagcatcc cccaccagat ccacctggga gagctgcacg 8820
ccattctgcg gcggcaggaa gatttttacc cattcctgaa ggacaaccgg gaaaagatcg 8880
agaagatcct gaccttccgc atcccctact acgtgggccc tctggccagg ggaaacagca 8940
gattcgcctg gatgaccaga aagagcgagg aaaccatcac cccctggaac ttcgaggaag 9000
tggtggacaa gggcgcttcc gcccagagct tcatcgagcg gatgaccaac ttcgataaga 9060
acctgcccaa cgagaaggtg ctgcccaagc acagcctgct gtacgagtac ttcaccgtgt 9120
ataacgagct gaccaaagtg aaatacgtga ccgagggaat gagaaagccc gccttcctga 9180
gcggcgagca gaaaaaggcc atcgtggacc tgctgttcaa gaccaaccgg aaagtgaccg 9240
tgaagcagct gaaagaggac tacttcaaga aaatcgagtg cttcgactcc gtggaaatct 9300
ccggcgtgga agatcggttc aacgcctccc tgggcacata ccacgatctg ctgaaaatta 9360
tcaaggacaa ggacttcctg gacaatgagg aaaacgagga cattctggaa gatatcgtgc 9420
tgaccctgac actgtttgag gacagagaga tgatcgagga acggctgaaa acctatgccc 9480
acctgttcga cgacaaagtg atgaagcagc tgaagcggcg gagatacacc ggctggggca 9540
ggctgagccg gaagctgatc aacggcatcc gggacaagca gtccggcaag acaatcctgg 9600
atttcctgaa gtccgacggc ttcgccaaca gaaacttcat gcagctgatc cacgacgaca 9660
gcctgacctt taaagaggac atccagaaag cccaggtgtc cggccagggc gatagcctgc 9720
acgagcacat tgccaatctg gccggcagcc ccgccattaa gaagggcatc ctgcagacag 9780
tgaaggtggt ggacgagctc gtgaaagtga tgggccggca caagcccgag aacatcgtga 9840
tcgaaatggc cagagagaac cagaccaccc agaagggaca gaagaacagc cgcgagagaa 9900
tgaagcggat cgaagagggc atcaaagagc tgggcagcca gatcctgaaa gaacaccccg 9960
tggaaaacac ccagctgcag aacgagaagc tgtacctgta ctacctgcag aatgggcggg 10020
atatgtacgt ggaccaggaa ctggacatca accggctgtc cgactacgat gtggaccata 10080
tcgtgcctca gagctttctg aaggacgact ccatcgacaa caaggtgctg accagaagcg 10140
acaagaaccg gggcaagagc gacaacgtgc cctccgaaga ggtcgtgaag aagatgaaga 10200
actactggcg gcagctgctg aacgccaagc tgattaccca gagaaagttc gacaatctga 10260
ccaaggccga gagaggcggc ctgagcgaac tggataaggc cggcttcatc aagagacagc 10320
tggtggaaac ccggcagatc acaaagcacg tggcacagat cctggactcc cggatgaaca 10380
ctaagtacga cgagaatgac aagctgatcc gggaagtgaa agtgatcacc ctgaagtcca 10440
agctggtgtc cgatttccgg aaggatttcc agttttacaa agtgcgcgag atcaacaact 10500
accaccacgc ccacgacgcc tacctgaacg ccgtcgtggg aaccgccctg atcaaaaagt 10560
accctaagct ggaaagcgag ttcgtgtacg gcgactacaa ggtgtacgac gtgcggaaga 10620
tgatcgccaa gagcgagcag gaaatcggca aggctaccgc caagtacttc ttctacagca 10680
acatcatgaa ctttttcaag accgagatta ccctggccaa cggcgagatc cggaagcggc 10740
ctctgatcga gacaaacggc gaaaccgggg agatcgtgtg ggataagggc cgggattttg 10800
ccaccgtgcg gaaagtgctg agcatgcccc aagtgaatat cgtgaaaaag accgaggtgc 10860
agacaggcgg cttcagcaaa gagtctatcc tgcccaagag gaacagcgat aagctgatcg 10920
ccagaaagaa ggactgggac cctaagaagt acggcggctt cgacagcccc accgtggcct 10980
attctgtgct ggtggtggcc aaagtggaaa agggcaagtc caagaaactg aagagtgtga 11040
aagagctgct ggggatcacc atcatggaaa gaagcagctt cgagaagaat cccatcgact 11100
ttctggaagc caagggctac aaagaagtga aaaaggacct gatcatcaag ctgcctaagt 11160
actccctgtt cgagctggaa aacggccgga agagaatgct ggcctctgcc ggcgaactgc 11220
agaagggaaa cgaactggcc ctgccctcca aatatgtgaa cttcctgtac ctggccagcc 11280
actatgagaa gctgaagggc tcccccgagg ataatgagca gaaacagctg tttgtggaac 11340
agcacaagca ctacctggac gagatcatcg agcagatcag cgagttctcc aagagagtga 11400
tcctggccga cgctaatctg gacaaagtgc tgtccgccta caacaagcac cgggataagc 11460
ccatcagaga gcaggccgag aatatcatcc acctgtttac cctgaccaat ctgggagccc 11520
ctgccgcctt caagtacttt gacaccacca tcgaccggaa gaggtacacc agcaccaaag 11580
aggtgctgga cgccaccctg atccaccaga gcatcaccgg cctgtacgag acacggatcg 11640
acctgtctca gctgggaggc gacaaaaggc cggcggccac gaaaaaggcc ggccaggcaa 11700
aaaagaaaaa gggaagcgga gctactaact tcagcctgct gaagcaggct ggagacgtgg 11760
aggagaaccc tggacctatg gtgagcaagg gcgaggagga taacatggcc atcatcaagg 11820
agttcatgcg cttcaaggtg cacatggagg gctccgtgaa cggccacgag ttcgagatcg 11880
agggcgaggg cgagggccgc ccctacgagg gcacccagac cgccaagctg aaggtgacca 11940
agggtggccc cctgcccttc gcctgggaca tcctgtcccc tcagttcatg tacggctcca 12000
aggcctacgt gaagcacccc gccgacatcc ccgactactt gaagctgtcc ttccccgagg 12060
gcttcaagtg ggagcgcgtg atgaacttcg aggacggcgg cgtggtgacc gtgacccagg 12120
actcctccct gcaagacggc gagttcatct acaaggtgaa gctgcgcggc accaacttcc 12180
cctccgacgg ccccgtaatg cagaaaaaaa ccatgggctg ggaggcctcc tccgagcgga 12240
tgtaccccga ggacggcgcc ctgaagggcg agatcaagca gaggctgaag ctgaaggacg 12300
gcggccacta cgacgctgag gtcaagacca cctacaaggc caagaagccc gtgcagctgc 12360
ccggcgccta caacgtcaac atcaagttgg acatcacctc ccacaacgag gactacacca 12420
tcgtggaaca gtacgaacgc gccgagggcc gccactccac cggcggcatg gacgagctgt 12480
acaagtaaga attcccccgg atctttgtga aggaacctta cttctgtggt gtgacataat 12540
tggacaaact acctacagag atttaaagct ctaaggtaaa tataaaattt ttaagtgtat 12600
aatgtgttaa actactgatt ctaattgttt gtgtatttta gattccaacc tatggaactg 12660
atgaatggga gcagtggtgg aatgccttta atgaggaaaa cctgttttgc tcagaagaaa 12720
tgccatctag tgatgatgag gctactgctg actctcaaca ttctactcct ccaaaaaaga 12780
agagaaaggt agaagacccc aaggactttc cttcagaatt gctaagtttt ttgagtcatg 12840
ctgtgtttag taatagaact cttgcttgct ttgctattta caccacaaag gaaaaagctg 12900
cactgctata caagaaaatt atggaaaaat attctgtaac ctttataagt aggcataaca 12960
gttataatca taacatactg ttttttctta ctccacacag gcatagagtg tctgctatta 13020
ataactatgc tcaaaaattg tgtaccttta gctttttaat ttgtaaaggg gttaataagg 13080
aatatttgat gtatagtgcc ttgactagag atcataatca gccataccac atttgtagag 13140
gttttacttg ctttaaaaaa cctcccacac ctccccctga acctgaaaca taaaatgaat 13200
gcaattgttg ttgttaactt gtttattgca gcttataatg gttacaaata aagcaatagc 13260
atcacaaatt tcacaaataa agcatttttt tcactgcatt ctagttgtgg tttgtccaaa 13320
ctcatcaagg taccaaaaaa gcaccgactc ggtgccactt tttcaagttg ataacggact 13380
agccttattt taacttgcta tttctagctc taaaaccagg cccatcctca caatcacggt 13440
gtttcgtcct ttccacaaga tatataaagc caagaaatcg aaatactttc aagttacggt 13500
aagcatatga tagtccattt taaaacataa ttttaaaact gcaaactacc caagaaatta 13560
ttactttcta cgtcacgtat tttgtactaa tatctttgtg tttacagtca aattaattcc 13620
aattatctct ctaacagcct tgtatcgtat atgcaaatat gaaggaatca tgggaaatag 13680
gccctcagat ctgcgaagat acggccacgg gtgctcttga tcctgtggct gattttggac 13740
tgtgctgctc gcagctgctg atgaatcaca tacttcctcc attttcttcc actgattgac 13800
tgttataatt tccctaattt ccaggtcaag gtgctgtgca ttgtggtaat agatgtgaca 13860
tgacgtcact tccaaaggac caatgaacat gtctgaccaa tttcatataa tgtgaaaacg 13920
attttcatag gcagaataaa taacatttaa attaaactgg gcatcagcgc aattcaattg 13980
gtttggtaat agcaagggaa aatagaatga agtgatctcc aaaaaataag tactttttga 14040
ctgtaaataa aattgtaagg agtaaaaagt actttttttt ctaaaaaaat gtaattaagt 14100
aaaagtaaaa gtattgattt ttaattgtac tcaagtaaag taaaaatccc caaaaataat 14160
acttaagtac agtaatcaag taaaattact caagtacttt acacctctgg ttcttgaccc 14220
cctaccttca gcaagcccag cagatccact agttctagag cggccgccac cgcggtggag 14280
ctccagcttt tgttcccttt agtgagggtt aattgcgcgc ttggcgtaat catggtcata 14340
gctgtttcct gtgtgaaatt gttatccgct cacaattcca cacaacatac gagccggaag 14400
cataaagtgt aaagcctggg gtgcctaatg agtgagctaa ctcacattaa ttgcgttgcg 14460
ctcactgccc gctttccagt cgggaaacct gtcgtgccag ctgcattaat gaatcggcca 14520
acgcgcgggg agaggcggtt tgcgtattgg gcgctcttcc gcttcctcgc tcactgactc 14580
gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct cactcaaagg cggtaatacg 14640
gttatccaca gaatcagggg ataacgcagg aaagaacatg tgagcaaaag gccagcaaaa 14700
ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc cataggctcc gcccccctga 14760
cgagcatcac aaaaatcgac gctcaagtca gaggtggcga aacccgacag gactataaag 14820
ataccaggcg tttccccctg gaagctccct cgtgcgctct cctgttccga ccctgccgct 14880
taccggatac ctgtccgcct ttctcccttc gggaagcgtg gcgctttctc atagctcacg 14940
ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag ctgggctgtg tgcacgaacc 15000
ccccgttcag cccgaccgct gcgccttatc cggtaactat cgtcttgagt ccaacccggt 15060
aagacacgac ttatcgccac tggcagcagc cactggtaac aggattagca gagcgaggta 15120
tgtaggcggt gctacagagt tcttgaagtg gtggcctaac tacggctaca ctagaaggac 15180
agtatttggt atctgcgctc tgctgaagcc agttaccttc ggaaaaagag ttggtagctc 15240
ttgatccggc aaacaaacca ccgctggtag cggtggtttt tttgtttgca agcagcagat 15300
tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc ttttctacgg ggtctgacgc 15360
tcagtggaac gaaaactcac gttaagggat tttggtcatg agattatcaa aaaggatctt 15420
cacctagatc cttttaaatt aaaaatgaag ttttaaatca atctaaagta tatatgagta 15480
aacttggtct gacagttacc aatgcttaat cagtgaggca cctatctcag cgatctgtct 15540
atttcgttca tccatagttg cctgactccc cgtcgtgtag ataactacga tacgggaggg 15600
cttaccatct ggccccagtg ctgcaatgat accgcgagac ccacgctcac cggctccaga 15660
tttatcagca ataaaccagc cagccggaag ggccgagcgc agaagtggtc ctgcaacttt 15720
atccgcctcc atccagtcta ttaattgttg ccgggaagct agagtaagta gttcgccagt 15780
taatagtttg cgcaacgttg ttgccattgc tacaggcatc gtggtgtcac gctcgtcgtt 15840
tggtatggct tcattcagct ccggttccca acgatcaagg cgagttacat gatcccccat 15900
gttgtgcaaa aaagcggtta gctccttcgg tcctccgatc gttgtcagaa gtaagttggc 15960
cgcagtgtta tcactcatgg ttatggcagc actgcataat tctcttactg tcatgccatc 16020
cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag tcattctgag aatagtgtat 16080
gcggcgaccg agttgctctt gcccggcgtc aatacgggat aataccgcgc cacatagcag 16140
aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg cgaaaactct caaggatctt 16200
accgctgttg agatccagtt cgatgtaacc cactcgtgca cccaactgat cttcagcatc 16260
ttttactttc accagcgttt ctgggtgagc aaaaacagga aggcaaaatg ccgcaaaaaa 16320
gggaataagg gcgacacgga aatgttgaat actcatactc ttcctttttc aatattattg 16380
aagcatttat cagggttatt gtctcatgag cggatacata tttgaatgta tttagaaaaa 16440
taaacaaata ggggttccgc gcacatttcc ccgaaaagtg ccacctaaat tgtaagcgtt 16500
aatattttgt taaaattcgc gttaaatttt tgttaaatca gctcattttt taaccaatag 16560
gccgaaatcg gcaaaatccc ttataaatca aaagaataga ccgagatagg gttgagtgtt 16620
gttccagttt ggaacaagag tccactatta aagaacgtgg actccaacgt caaagggcga 16680
aaaaccgtct atcagggcga tggcccacgc tggctaagaa ctcatcagcc tccccggtcc 16740
atctacccac gtaccaatgc accaattggc cacaatgacg gctactacat ggtgccattc 16800
cttcctcttt ataggaatgg agactacctc ctgtccaaca aggctcttgg atacgagtac 16860
gcctacctgt tggacccagg tcattgcaca acaccagaaa tgccctctga tctgcaaaag 16920
acgtgaatat ctgttcagac acccatatcc actctgttcc acacaggtca gaggtttgtc 16980
caggagttct tgacagaggt gtaaaaagta ctcaaaaatt ttactcaagt gaaagtacaa 17040
gtacttaggg aaaattttac tcaattaaaa gtaaaagtat ctggctagaa tcttacttga 17100
gtaaaagtaa aaaagtactc cattaaaatt gtacttgagt attaaggaag taaaagtaaa 17160
agcaagaaag aaaactagag attcttgttt aagcttttaa tctcaaaaaa cattaaatga 17220
aatgcataca aggttttatc ctgctttaga actgtttgta tttaattatc aaactataag 17280
acagacaatc taatgccagt acacgctact caaagttgta aaacctcaga tttaacttca 17340
gtagaagctg attctcaaaa ttgttagtgt caagcctagc tcttttgggg ctgaaaagca 17400
atcctgcagt gctgaaaagc ctctcacagg cagccgatgc gggaagaggt gtattagtct 17460
tgatagagag gctgcaaata gcaggaaacg tgagcagaga ctccctggtg tctgaaacac 17520
aggccagatg ggcc 17534
<210> 2
<211> 7416
<212> DNA
<213> Artificial
<220>
<223> GFAP
<400> 2
ctcgaggtaa ggactgaggt gatgcacagt gttgggtatg ttactttcaa taagttattc 60
tttgctaatt attagtcatt tgaattgtat tgaaattaca tttttagtta ctttgcctaa 120
aaaaaaactt gataagtaat cgaattacat acttgaagtc cacataaatc tcattcattc 180
attccttctc ttttcgactt agtcccttta ttaatcaggg gtttctacag cggaacgaac 240
ctcatatgtt tcaatttagt gactattttt tataaattat tgacaatgtt tttgttgctt 300
gttcaaacta cttatttaaa atgagctgaa actgcacaat tattgatatt tcattggaac 360
agcttaattt tttttatgtt taatccactt aaataaaatt ccaattatat aatattccaa 420
ttataaagtt acttaatcaa tttgtattag gacaatatga atgaattgtg tggaaccctg 480
cattttttac agtgaacctt tccttgtttc ttaaacatgg gtgattttcg gagaaataaa 540
atttgacaat atctgaaatg taaaaagaaa atattcagtt actctgcctt tctaaatgca 600
tagtttatat tatcatcaga gttgtaaagt aactagttac aaatactcaa attactgtaa 660
ttgagtagtt tttttcagga attgtaattt actaagtagc taaaaaatgt gtacttttac 720
tttcccttga gtacattatt aatgctgtaa cggtactttt actccactac tttccttcag 780
cctgcactca ctactttgtt ttatcttgtc tatgaggatt agaaaaatca atcctgtgat 840
tccaatcaaa tcgcacatcc aaagtcttta caaaagcatt ttgtttggat gtgaaaatcg 900
ggttgatgtc agaactcaat gtcagcccaa cgtcaatgtc caacctaaaa tcaacctaat 960
atcaacgtct aatgatgtta cagcttgacg ttgtgtgggc gttaccatta tttgtcagac 1020
attggatttt agttgccata cctgataaat aaatgtcagt atttgatgtc cgtatgatct 1080
tggatttaga tgttggctcg acattggatt ttggtcacct gacataacaa cctaaatcta 1140
tcctaataat aacgtcttat gacgttgtgt gccaaccatt tttgtttatt aaaaatttat 1200
ataaacattt acaataatat attatccatg tgatttaata gaaatgttat ttgttttttt 1260
tctcccccat atttctgaat gacttaaagc ttttattatc aggataaggt tgtggttttt 1320
attttttgct tgctaacttc aattgctatt gcatttacat ttatgcaaat ggggagacgc 1380
ggtgggtcag ttggcgtttc tgtgtggagt ttgcatgttc tccccgtgtt cgcgtgggtt 1440
ttctctgggt gctctggttt cccctaaaga catgtagtat aggtgaattg ggtaagctaa 1500
attgtccgta gtgtgtatgt gtgaatgtat ggatgttttc ctgtgatggg ttgcagctga 1560
aagggcatcc gctgtgtaaa acatatgctg gataagttgg caattcattt cgctgtggta 1620
accccagatt aatatcggaa ctacgccaaa aagaaaatga atgaatgagt gaattaatgc 1680
aaatggctca tccttccacc taattccagt gccttgcatt gcattcaagc tctacaatta 1740
atcagttcct ttattttcac tttccaaact gaatccaaca actcatgagg accccagggt 1800
gccttgattt accagtgtca tgatgaacac aatctacccc actttaaccc actcgtcaac 1860
ataaatactc ccttaaaggg tgtacttgtg tctgagtaga agtgtctgct gggttggagg 1920
tgtcgcacat tccaggacac gtcaagaaga acgctaagag caacaggaga acaatgtcac 1980
aaaaaaggtc aaagaaacgc catccattag ccagctttat aaacagctgt ctcgtggcta 2040
aagaagttct caagaataac caaccttgca tttttccaca ttagttttac accgcagcaa 2100
agtcaccatg tggatttata gcatccaaac cccattttca atgagaggct tcacatttct 2160
cgctctcatt caatcccaca ctgcctctct tttcagacta aatcctgata ggatgagtgg 2220
tatgggggcg gggagggggc acaatacctc agtccagctt ccacaaagac tcaacacacc 2280
catgcagatg tcctgttgtt ggggaagtgc atttgtaacc aaatttcaaa ctttcaactt 2340
tcatttgaag cagtggagac tgctccattc ctattcaaga tcaatttatt gaaatatgac 2400
aacatttaga ataactttgt tatatgttat tatgttttat aatgcaattt tgtttctgtg 2460
acatacattt ttttatttag tgcagtcttc agagccacag gaaccttgag aatcattcta 2520
attatgattt gctactcgaa aaacattttt catcatcaat aataagaaat taaaacggta 2580
tacatataga tgtttagtat aacagttctt agtagtttaa aagaacattt gtaacaacat 2640
tccaaccttt taataacttt agccttgctt acatttctaa aggagagcct tccagctgtt 2700
tttctgaacc cagtgatgaa tgtaaagttc ttaaaaccaa gttctaagaa tgttttaatg 2760
attacattta acccaatttc aagccaaatt tcctatacca cgagtaaaat atagttataa 2820
ttaggataga tctttggtaa aataagatac aattttaaga tttgaattta aaagtagcta 2880
aattgttttt ttatgacaga acttttaagt ttatagaata ttaatacagg acaaaacttg 2940
taaatgtatt taatttccta tgaatatttg ataaaatata aatgacatct atatgtaaat 3000
tcatgaacca tgactcttat gaattatcag tgcacaaatt atgtttgatg cacacttaag 3060
gtcaaaagtt tagggtcagt ttattttttt ttttattttt aattttattt aataatttaa 3120
ataaaattat tctgttcatc aaggcacatt tattaaatgt aacaataaat tgttaaatac 3180
ttattaaata tttatttttt acttattgta tgcagtttca attgaagtca ttattgcttt 3240
tattactatt accattaata aaaataacat taataataat aataataata ataataattg 3300
atattacagt gatttctgaa ggatcacgtg actgaagact ggagtaatga agctgaaaac 3360
tcatcattta aatcactgga gtaaatgatt caattaaatg atcatttaat gatcattctt 3420
ttgaacagtt attttatagt gcaataacat ttcacagttt taccatttgt tttgtatttt 3480
tgattcaata aatgcagcct tggtgagcag gagaagctta atttaaaaca tttaaaactc 3540
ctactgaccc caaacttttg accggtagtg tacatgtatt actgtatgtt caaactatat 3600
gcttttattc ataagtgttt ctattgctgt acatttgact gtctgcatca ggtgaagtgt 3660
atgaaagagt gtgtgtttac tccaccccgt gggaaagagc agtagctgca atgtgtgtgt 3720
gtgagtagtt agtgatgcat gagtgatcca ctgaaccctg tccagccccc tgctgcagct 3780
ctcaacacat catgataggt cacctctact gggaggcttt cagcacagct ctcacaactg 3840
atttatcaga gagtactctg aaatggagaa attactttca tattaaagag cacacacaca 3900
cacacacaca cacacacaca cacacacaca cacacacaca cacacacaca cacacctagt 3960
tcaccttatt aacgtggtta agcctttaaa tgtcacttta agctgtatag aagtgtcttg 4020
aaaaatatct attcaaatat tatttactgt catcaaggaa aagataaaat aaatcagtta 4080
ttagaaataa gtttttaaaa ctattatact tagaaatgtg ctgaaacaat cttcctagaa 4140
cagaacagaa attggggaaa aaataaacaa aaataaataa atctatctat ctatagtgtg 4200
tataatgtgt gtagtgagta tgtttaaaat aggtcaacta atatgttcat aataaaaata 4260
cagcatcaat ggtttgggtg tttttagatc caaaggtctt aaacgtggtt attgctggtt 4320
gttcagtttt ttctaggctc taagaaaaat cattttagaa actgtaactg tttccttatc 4380
catctgaatt ccacctttgg gatgtagtgg aacgggagat caactgcatg atgctatcaa 4440
gtcaatatgg atcaaaatct caggaatatt tccaggacct tattgaatct atgccatgaa 4500
ggattaaggc agttctgaaa ggggaaatgc ggtttaaccc ggtaatagca aggtgtacct 4560
aataaagtgg ccggtgagtg tatatattgt tattgtttca ccttcagaaa tgacatatct 4620
agacaatagt ttcctttttc ttttttaatt attgtacttc tgtaagattc ttcaatgttc 4680
aatggttttc ttatgttaaa ggcgcagagc tgtagtttta gtgaagtaac agcattccgt 4740
tgaccaaagc tgacagatga aggagagtca gttctgacct tgcagttgtc agtcacaatt 4800
aagcctggtt tggttacaag ttaaacgtag acctgcttgt ggtcaggatc atcctttaaa 4860
agaactagat ttgtttttaa caatttgtaa ccggtgtgct ctgaagtgtc ttaaataaag 4920
catataggaa gcaaagcagt gaaaaatgtt ccttataatc tacgagcatt agcttaaatg 4980
tataaacaaa ataatattaa ttgtgtgttc agatcaaata taggtattgt tacacctaaa 5040
ataaacccat tgctttaaaa aataattaaa cacagtgtac aatattagca tacttcctct 5100
gacatctcta agtaaaacaa gagctttcac gatttactca ctgacccatc ttacagcact 5160
tctctgtgaa tttaggccat cacaaatgct gtgcccagtt ctctgactgg gtttgacagt 5220
cgcccatctg tgtccagcag tctgatgagc tcatcctctg taaatctggc tggctgccgt 5280
gttgttttgt gtctgtccgt gagtctctct ggccttcata cactcctctg ctacttcata 5340
gactgctgat gagtgcagag gccaaaccat tagtgctttt cttttttttt agacctcagt 5400
aatgcacaac aatgcaaaac aagtagattg agccttttgt tctttggact gagcatttgg 5460
ttagaatagc ttgaagggat agttagaaga tattttgaag ggaaactaaa aacctgttac 5520
catttgacat ccaaagaagg aaaactaata tgattgagtg gttacagatt tccaacactt 5580
ttcaacatat attattttgt gttccactaa agaaacagtc aaatattata ctgtcaacca 5640
aagtactgca cttgactcaa aaaagctctg cagcaagttg cctcttattc taggtcgagt 5700
caaccttttt ttctctctct ctgtcggttc attcaaggtt cagtaaatga tgacagaatt 5760
ttcagctttt attttgggtg aactaaccct ttatatattt gttgtaagtt tatttttctg 5820
tatattataa atatattagc aacataattc taagctacac ttgtacccaa tcaagggtca 5880
cactttattt tgatggtatg tttgtttgaa tttaagttac attgcatcta catgtcaact 5940
aattctcatt agattataag aagactgtta ggttggggtt agtgtaagtt gacatgtact 6000
tgcaaagttt ctcagagtca gttaaatgtc tgttttgtag cagtattaac agatattaag 6060
cacactgtat attaatactc aaatgaaccg tcaaaataaa gtgttaccgt aaaaattatt 6120
tccacatctc aaggtagctt tatgaggaaa gttttcttta agattagttt cttcgaacaa 6180
acttgcatgt taaatatgtg ctcagatatg gggcacacag acaaaatgtt tattggacga 6240
ataacccctt taacagttaa ccagcatttt ttaaagggat agtcagaaga tattttgaag 6300
gaaactaaaa acctgtaacc attcgacaat cgaagaaggt aaaagaaata tgatagagta 6360
gttacagttt ttcaacactc tttataatat attgtttagt attcaactga agaaatagtc 6420
aaacacactg taaaaaaagt tggtttaaat tgactcaact ttcaactcaa gtatagtact 6480
tgacttgatt taagttgagt taactagact aaactaaaag cactaaaagc actgcggcaa 6540
gtcgcctttc aattttaggt tgagtaaatt attattattt ttttttacag ttcaggttca 6600
gtaaatgata acataatttt cagttttggg tgaactatcc ctttatatat ttgttgtaag 6660
ttaatttttc tgtaaattat aaattaatta gcaaaaaagc tgcacttctt caccattaat 6720
taattaatac atctcaaagt agctttataa ggaaagtttt ctttaattat gtttctttgc 6780
atgttaaaat tgtgctcaga tatggagcac acaagcaaaa tgtttattgg atgaataacc 6840
cctttaacat ttaaccagca tgagttcaag taaacaaatc aattcctatg atttttctgc 6900
taaaccgata taaatcagtg ctgctgaaga gcatgtgtgt gatgttctca gatcagcaca 6960
aaagagggag cgccagtttc ttttaataat gaagaattac gtaatcacct cctgtgttcc 7020
ctgaaaccat taaactccca gacagaacaa aactgtgact gagaaagcag agcaactccg 7080
gagtaactca gaagatctgc aaaccaactc tttagcatga ggtaagagag aattaaagtc 7140
caatatcagt gctgatgcca tctcagtctc tctatttctg tgttccagca gggtatgaat 7200
aggattttct ctgactcact gtgaaaagag gcagtcagga gactggctgg acaagcacaa 7260
acaattgcgg gctcacaaac accccctcgg cctttgccct ccccatcaga ccccccctct 7320
ctctttcacc ccccacatca actctataaa aacccagagt tcacccgcac tcgatctcat 7380
tctcctccac catggagtcc cagcgttcct gtcgac 7416
<210> 3
<211> 711
<212> DNA
<213> Artificial
<220>
<223> mCherry
<400> 3
atggtgagca agggcgagga ggataacatg gccatcatca aggagttcat gcgcttcaag 60
gtgcacatgg agggctccgt gaacggccac gagttcgaga tcgagggcga gggcgagggc 120
cgcccctacg agggcaccca gaccgccaag ctgaaggtga ccaagggtgg ccccctgccc 180
ttcgcctggg acatcctgtc ccctcagttc atgtacggct ccaaggccta cgtgaagcac 240
cccgccgaca tccccgacta cttgaagctg tccttccccg agggcttcaa gtgggagcgc 300
gtgatgaact tcgaggacgg cggcgtggtg accgtgaccc aggactcctc cctgcaagac 360
ggcgagttca tctacaaggt gaagctgcgc ggcaccaact tcccctccga cggccccgta 420
atgcagaaaa aaaccatggg ctgggaggcc tcctccgagc ggatgtaccc cgaggacggc 480
gccctgaagg gcgagatcaa gcagaggctg aagctgaagg acggcggcca ctacgacgct 540
gaggtcaaga ccacctacaa ggccaagaag cccgtgcagc tgcccggcgc ctacaacgtc 600
aacatcaagt tggacatcac ctcccacaac gaggactaca ccatcgtgga acagtacgaa 660
cgcgccgagg gccgccactc caccggcggc atggacgagc tgtacaagta a 711
<210> 4
<211> 241
<212> DNA
<213> Artificial
<220>
<223> U6启动子
<400> 4
gtcctttcca caagatatat aaagccaaga aatcgaaata ctttcaagtt acggtaagca 60
tatgatagtc cattttaaaa cataatttta aaactgcaaa ctacccaaga aattattact 120
ttctacgtca cgtattttgt actaatatct ttgtgtttac agtcaaatta attccaatta 180
tctctctaac agccttgtat cgtatatgca aatatgaagg aatcatggga aataggccct 240
c 241
Claims (10)
1.一种基因敲除载体,其特征在于,所述基因敲除载体为将目的序列连入可表达CRISPR-Cas9基因编辑系统相关酶的质粒获得,所述目的序列选自如下序列中的至少一种:
rb1:TGCATGGAGAATATGGGAGA;
nf1:GGCGCACAAGCCCGTGGAAT;
tp53:TGATTGTGAGGATGGGCCTG。。
2.根据权利要求1所述的基因敲除载体,其特征在于:所述可表达CRISPR-Cas9基因编辑系统相关酶的质粒为Cas9-pXT7质粒;
和/或,所述基因敲除载体还含有标记基因mCherry。
3.根据权利要求1所述的基因敲除载体,其特征在于:所述基因敲除载体还含有GFAP启动子启动的CAS9蛋白序列、融合蛋白P2A序列、标记基因mCherry、U6启动子启动的gRNA。
4.根据权利要求3所述的基因敲除载体,其特征在于:所述基因敲除载体序列如SEQ IDNO.1所示。
5.根据权利要求1-4任一项所述基因敲除载体在构建胶质瘤动物模型中的用途。
6.根据权利要求5所述的用途,其特征在于:所述动物模型包括鱼、鼠、兔,优选为斑马鱼。
7.一种建立斑马鱼胶质瘤模型的方法,包括如下步骤:
1)确立p53、Rb1和Nf1基因打靶位点以及打靶序列,合成gRNA;
p53、Rb1和Nf1基因含有如下目标序列:
rb1:TGCATGGAGAATATGGGAGA;
nf1:GGCGCACAAGCCCGTGGAAT;
tp53:TGATTGTGAGGATGGGCCTG;
2)构建基因敲除转座重组载体;
3)将基因敲除转座重组载体和Tol2mRNA共同注射入斑马鱼单细胞期受精卵中,实现目的基因整合进入基因组;
4)筛选并鉴定出能够稳定敲除上述三种基因的纯种斑马鱼;
5)筛选出双基因或多基因敲除的纯系斑马鱼。
8.根据权利要求7所述的方法,其特征在于:步骤2)中,所述重组载体包括GFAP启动子启动的CAS9蛋白序列、融合蛋白P2A序列、标记基因mCherry、U6启动子启动的gRNA;
和/或,所述重组载体序列如SEQ ID NO.1所示;
和/或,步骤2)中所构建的重组载体Cas9的启动子为GFAP,序列如SEQ ID NO.2所示;
和/或,步骤2)中所构建的重组载体的筛选基因为红色荧光蛋白mCherry,序列如SEQID NO.3所示;
和/或,步骤2)中所构建的重组载体靶位点的启动子为U6启动子,序列如SEQ ID NO.4所示。
9.根据权利要求7所述的方法,其特征在于:步骤4)中,获得单敲斑马鱼纯合体F3的步骤如下:选择生殖细胞中表达红色荧光的嵌合体F0代,培养至成鱼,剪尾T7E1检测基因敲除情况,将基因被敲除的F0代和野生型斑马鱼进行杂交,后代中如果仍然有荧光且基因被敲除的个体,属于杂合体F1,将杂合体F1的单个个体与野生型斑马鱼再次进行杂交,后代中仍然有荧光且基因被敲除的个体为杂合体F2,将杂合体F2中的雌鱼和雄鱼进行杂交,在杂交得到的后代中,筛选得到GFAP启动子启动特定荧光蛋白表达且组织特异性基因敲除的斑马鱼的纯合体F3,运用T7E1检测获得纯合敲除基因型斑马鱼。
10.根据权利要求7所述的方法,其特征在于:步骤5)中,将单基因敲除的纯合斑马鱼进行两两杂交,获得双基因敲除的纯合斑马鱼,再将双基因敲除的斑马鱼与另一单基因敲除的纯合斑马鱼杂交,获得多基因敲除的斑马鱼胶质瘤模型。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810011807.3A CN107988246A (zh) | 2018-01-05 | 2018-01-05 | 一种基因敲除载体及其斑马鱼胶质瘤模型 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810011807.3A CN107988246A (zh) | 2018-01-05 | 2018-01-05 | 一种基因敲除载体及其斑马鱼胶质瘤模型 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107988246A true CN107988246A (zh) | 2018-05-04 |
Family
ID=62040802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810011807.3A Pending CN107988246A (zh) | 2018-01-05 | 2018-01-05 | 一种基因敲除载体及其斑马鱼胶质瘤模型 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107988246A (zh) |
Cited By (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108753834A (zh) * | 2018-05-28 | 2018-11-06 | 上海海洋大学 | ddx27基因缺失斑马鱼突变体的制备方法 |
| CN109439662A (zh) * | 2018-11-15 | 2019-03-08 | 北京大学第三医院 | 用于C5aR1基因敲除的sgRNA、载体以及构建方法和检测方法 |
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
| US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
| US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
| CN111149730A (zh) * | 2019-12-25 | 2020-05-15 | 湖南师范大学 | 一种快速培育多能干细胞荧光标记斑马鱼纯合个体的方法 |
| US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| CN111363834A (zh) * | 2020-04-30 | 2020-07-03 | 华中农业大学 | 与克氏原螯虾白斑综合征病抗性相关的snp分子标记 |
| US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
| US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN117987466A (zh) * | 2024-01-10 | 2024-05-07 | 汕头大学医学院 | 一种模拟人类阿尔茨海默症tau蛋白聚集介导疾病发生、发展过程的方法 |
| CN118120703A (zh) * | 2024-03-18 | 2024-06-04 | 华南理工大学 | 一种rb1突变体在神经退行性疾病中的应用 |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
-
2018
- 2018-01-05 CN CN201810011807.3A patent/CN107988246A/zh active Pending
Cited By (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US12006520B2 (en) | 2011-07-22 | 2024-06-11 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
| US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
| US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
| US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
| US12473573B2 (en) | 2013-09-06 | 2025-11-18 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
| US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
| US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
| US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| US12215365B2 (en) | 2013-12-12 | 2025-02-04 | President And Fellows Of Harvard College | Cas variants for gene editing |
| US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
| US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
| US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US12398406B2 (en) | 2014-07-30 | 2025-08-26 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| US12344869B2 (en) | 2015-10-23 | 2025-07-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US11999947B2 (en) | 2016-08-03 | 2024-06-04 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US12084663B2 (en) | 2016-08-24 | 2024-09-10 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| US12516308B2 (en) | 2017-03-09 | 2026-01-06 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| US12435331B2 (en) | 2017-03-10 | 2025-10-07 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| US12359218B2 (en) | 2017-07-28 | 2025-07-15 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| CN108753834B (zh) * | 2018-05-28 | 2021-11-23 | 上海海洋大学 | ddx27基因缺失斑马鱼突变体的制备方法 |
| CN108753834A (zh) * | 2018-05-28 | 2018-11-06 | 上海海洋大学 | ddx27基因缺失斑马鱼突变体的制备方法 |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| CN109439662A (zh) * | 2018-11-15 | 2019-03-08 | 北京大学第三医院 | 用于C5aR1基因敲除的sgRNA、载体以及构建方法和检测方法 |
| CN109439662B (zh) * | 2018-11-15 | 2020-09-01 | 北京大学第三医院 | 用于C5aR1基因敲除的sgRNA、载体以及构建方法和检测方法 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US12509680B2 (en) | 2019-03-19 | 2025-12-30 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US12281303B2 (en) | 2019-03-19 | 2025-04-22 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN111149730A (zh) * | 2019-12-25 | 2020-05-15 | 湖南师范大学 | 一种快速培育多能干细胞荧光标记斑马鱼纯合个体的方法 |
| CN111149730B (zh) * | 2019-12-25 | 2021-04-13 | 湖南师范大学 | 一种快速培育多能干细胞荧光标记斑马鱼纯合个体的方法 |
| CN111363834A (zh) * | 2020-04-30 | 2020-07-03 | 华中农业大学 | 与克氏原螯虾白斑综合征病抗性相关的snp分子标记 |
| US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| US12031126B2 (en) | 2020-05-08 | 2024-07-09 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN117987466A (zh) * | 2024-01-10 | 2024-05-07 | 汕头大学医学院 | 一种模拟人类阿尔茨海默症tau蛋白聚集介导疾病发生、发展过程的方法 |
| CN118120703B (zh) * | 2024-03-18 | 2025-10-17 | 华南理工大学 | 一种rb1突变体在神经退行性疾病中的应用 |
| CN118120703A (zh) * | 2024-03-18 | 2024-06-04 | 华南理工大学 | 一种rb1突变体在神经退行性疾病中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107988246A (zh) | 一种基因敲除载体及其斑马鱼胶质瘤模型 | |
| CN111909958B (zh) | 血管平滑肌细胞条件性敲除Yap1基因小鼠模型的构建 | |
| KR101992494B1 (ko) | 제초제 내성 대두 식물 및 그의 동정 방법 | |
| CN107502618B (zh) | 可控载体消除方法及易用型CRISPR-Cas9工具 | |
| CN108849774B (zh) | 一种阻断蚕蛾出茧的方法 | |
| CN112746083B (zh) | 一种通过单碱基编辑靶基因启动子失活基因的方法 | |
| CN109735479B (zh) | 一种合成2’-岩藻糖基乳糖的重组枯草芽孢杆菌及其构建方法与应用 | |
| CN110343698B (zh) | 构建B2m定点敲入人B2M cDNA小鼠模型的方法 | |
| KR101755965B1 (ko) | Il33 n―말단 도메인 결실을 갖는 염증의 쥣과 모델 | |
| CN112680477B (zh) | 一种基于无缝克隆技术的h9n2亚型禽流感病毒的拯救方法 | |
| CA2501708C (en) | Mammalian artificial chromosome | |
| Chrysostomou et al. | Gene manipulation in Hydractinia | |
| CN113493800B (zh) | 一种提高酿酒酵母中异源蛋白分泌或表面展示表达的方法 | |
| CN116497052A (zh) | 一种生产虾青素的解脂耶氏酵母基因工程菌的构建方法 | |
| CN110331164B (zh) | Lilra3基因敲入小鼠的打靶载体和lilra3基因敲入小鼠的构建方法 | |
| CN111378677A (zh) | 一种dna组装的方法及其应用 | |
| CN107988202B (zh) | 一种敲除酿酒酵母染色体的方法 | |
| CN115247166B (zh) | 一种蛋白酶突变体 | |
| CN112342216B (zh) | 用于提高CHO细胞的表达效率的CRISPR-Cas13d系统以及重组CHO细胞 | |
| KR20190096910A (ko) | 담즙산에 의해 발현이 유도되는 pedv 백신 제조용 표면발현 벡터, 그에 의해 형질전환된 형질전환유산균과 이들 pedv 백신용 표면발현벡터 및 형질전환된 재조합 유산균의 제조방법 | |
| CN117561273A (zh) | 用于经改善的磷酸转移酶的材料和方法 | |
| CN112342240B (zh) | 用于表达rFC蛋白的59R突变载体及其制备方法和应用 | |
| CN112359059B (zh) | 用于表达rFC蛋白的84E突变载体及其制备方法和应用 | |
| CN108277232A (zh) | 一种润肠功能的富硒酵母及其制备方法 | |
| KR102009266B1 (ko) | 구제역 sat2형 zim의 방어항원이 발현되는 재조합 바이러스 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180504 |
|
| RJ01 | Rejection of invention patent application after publication |